title: Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
authors.affiliation: New York University School of Medicine, New York.
authors.forename: Siyao
authors.initials: S
authors.lastname: Liu
authors.affiliation: New York University School of Medicine, New York.
authors.forename: Cherub O
authors.initials: CO
authors.lastname: Kim
authors.affiliation: Division of Medical Toxicology, New York University School of Medicine, New York.
authors.forename: Scott N
authors.initials: SN
authors.lastname: Lucyk
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D000991:Antithrombins / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001562:Benzimidazoles / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D014859:Warfarin / Q000009:adverse effects*; D015091:beta-Alanine / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin